Form D · Biotechnology
InflammX Therapeutics, Inc.
Tampa, FL · CIK 0001840051
Offering snapshot reported May 23, 2022 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 6, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 23, 2022 | Initial | $0 | No comparison | 2 | SEC filing |
| Nov 19, 2021 | Initial | $8,355,060 | No comparison | 6 | SEC filing |
| Jan 13, 2021 | Initial | $7,029,425 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-446531
Shares issued as consideration for rights granted to the Issuer under a certain acquisition agreement.
Source: Form D, filed May 23, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Blair | Director |
| David Boyer | Director |
| Brian Levy | Director, Executive |
| David Pool | Executive |
| Phil Rosenfeld | Director |
| Richard Rubino | Director |
| Rajiv Shukla | Director |
| Jason Werner | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
275 Bayshore Blvd, Unit 1607
Tampa, FL, 33606
Tampa, FL, 33606